These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 23668408)

  • 21. A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder.
    Denys D; van der Wee N; van Megen HJ; Westenberg HG
    J Clin Psychopharmacol; 2003 Dec; 23(6):568-75. PubMed ID: 14624187
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe.
    Segura M; Farré M; Pichini S; Peiró AM; Roset PN; Ramírez A; Ortuño J; Pacifici R; Zuccaro P; Segura J; de la Torre R
    Clin Pharmacokinet; 2005; 44(6):649-60. PubMed ID: 15910012
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Remission rates in patients with anxiety disorders treated with paroxetine.
    Ballenger JC
    J Clin Psychiatry; 2004 Dec; 65(12):1696-707. PubMed ID: 15641876
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical experience with paroxetine in social anxiety disorder.
    Baldwin DS
    Int Clin Psychopharmacol; 2000 Jul; 15 Suppl 1():S19-24. PubMed ID: 10994679
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simultaneous measurement of serotonin and paroxetine in rat brain microdialysate by a single-pump column-switching technique.
    Ramaiya A; Karnes HT
    J Chromatogr B Biomed Sci Appl; 1997 Mar; 691(1):119-29. PubMed ID: 9140765
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A simple HPLC method for the simultaneous determination of two selective serotonin reuptake inhibitors and two serotonin-norepinephrine reuptake inhibitors in hair, nail clippings, and cerebrospinal fluid.
    Samanidou V; Pantazidou K; Kovatsi L; Njau S; Livanos A
    J Sep Sci; 2012 Apr; 35(7):839-45. PubMed ID: 22532352
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of paroxetine in the treatment of obsessive-compulsive disorders.
    Kamijima K; Aoki M
    Expert Rev Neurother; 2006 Jul; 6(7):945-56. PubMed ID: 16831110
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Pigott TA; Seay SM
    J Clin Psychiatry; 1999 Feb; 60(2):101-6. PubMed ID: 10084636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The selective serotonin reuptake inhibitor paroxetine is effective in more generalized and in less generalized social anxiety disorder.
    Stein DJ; Stein MB; Goodwin W; Kumar R; Hunter B
    Psychopharmacology (Berl); 2001 Nov; 158(3):267-72. PubMed ID: 11713616
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Paroxetine in Postmortem Fluids and Tissues from Nine Aviation Accident Victims.
    Lewis RJ; Kemp PM; Johnson RD
    J Anal Toxicol; 2015 Oct; 39(8):637-41. PubMed ID: 26378138
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paroxetine: an update of its use in psychiatric disorders in adults.
    Wagstaff AJ; Cheer SM; Matheson AJ; Ormrod D; Goa KL
    Drugs; 2002; 62(4):655-703. PubMed ID: 11893234
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vibrational circular dichroism spectroscopy study of paroxetine and femoxetine precursors.
    Urbanová M; Setnicka V; Bour P; Navrátilová H; Volka K
    Biopolymers; 2002; 67(4-5):298-301. PubMed ID: 12012452
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A fatal case due to combined toxicity of psychotropic drugs.
    Kinoshita H; Nishiguchi M; Kasuda S; Takahashi M; Ouchi H; Minami T; Matsui K; Ohtsu N; Yoshida S; Adachi N; Ameno K; Hishida S
    Forensic Sci Int; 2008 Oct; 181(1-3):e7-8. PubMed ID: 18818033
    [No Abstract]   [Full Text] [Related]  

  • 34. Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders.
    Gunasekara NS; Noble S; Benfield P
    Drugs; 1998 Jan; 55(1):85-120. PubMed ID: 9463792
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Obsessive-compulsive disorder: implications of the efficacy of an SSRI, paroxetine.
    Ninan PT
    Psychopharmacol Bull; 2003; 37 Suppl 1():89-96. PubMed ID: 14566204
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Paroxetine during lactation: is it really safe for the infant?
    de Vries TW; de Jong-van de Berg LT; Hadders-Algra M
    Acta Paediatr; 2004 Oct; 93(10):1406-7. PubMed ID: 15499967
    [No Abstract]   [Full Text] [Related]  

  • 37. Obsessive-compulsive spectrum disorders: effective treatment with paroxetine.
    Ravindran AV; Lapierre YD; Anisman H
    Can J Psychiatry; 1999 Oct; 44(8):805-7. PubMed ID: 10566112
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Efficacy and tolerability of escitalopram in anxiety disorders: a review].
    Pelissolo A
    Encephale; 2008 Sep; 34(4):400-8. PubMed ID: 18922243
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stability-indicating high performance thin layer chromatography determination of Paroxetine hydrochloride in bulk drug and pharmaceutical formulations.
    Venkatachalam A; Chatterjee VS
    Anal Chim Acta; 2007 Aug; 598(2):312-7. PubMed ID: 17719907
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of depression with comorbid anxiety disorders: differential efficacy of paroxetine versus moclobemide.
    Pini S; Amador XF; Dell'Osso L; Baldini Rossi N; Cassano P; Savino M; Cassano GB
    Int Clin Psychopharmacol; 2003 Jan; 18(1):15-21. PubMed ID: 12490770
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.